Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I dont but its just confusing on why there is a holdup?
So believe the guy on Stocktwits then.
Someone on stocktwits claiming they need to be current before anything happens
Does this have to be current for merger to hit to hit nasdaq?
I think it is.We shall see.
What happens after that
We shall see but by the end of May,RWOD will be worthless shell.....
So hilarious watching this clown show! Ultimately in the end…anyone holding shares is a big loser!! Tax write off in the making!!
Let see how the DR handle leas share holders
+>>>LEAS - LMFAO i'm still here. I want to see what happens!
Yes sir, just waiting to see what happens when RWOD becomes WENA, and what the LEAS converts into.
Merger Sub
Anew Medical Sub, Inc. is a wholly owned subsidiary of Redwoods formed solely for the purpose of effectuating the Merger described herein. Merger Sub was incorporated under the laws of Wyoming as a corporation on May 12, 2023. Merger Sub owns no material assets and does not operate any business.
The mailing address of Merger Sub’s principal executive office is 1115 Broadway, 12th Floor, New York, NY 10010. Its telephone number is (646) 916-5315. After the consummation of the business combination, Merger Sub will cease to exist as a separate legal entity.
ANEW
ANEW MEDICAL, INC. is a Wyoming corporation originally formed in Nevada on August 2, 2004 as Technigen Corp. On February 27, 2006, the company changed its name to Vision Dynamics Inc and on May 22, 2006, the company changed its name to Mommoth Energy Group, Inc. On March 5, 2013, the company as re-domiciled in Wyoming and on October 2, 2014 changed its name to Strategic Asset Leasing Inc. On January 4, 2022, Strategic Asset Leasing, Inc. (“LEAS”) officially changed its name to ANEW MEDICAL, INC. under the rules of the State of Wyoming. However, this name change has not been declared effective by FINRA. LEAS is referred to this proxy statement/prospectus supplement as “ANEW MEDICAL, INC.,” “ANEW” or “ANEW MEDICAL”. Upon closing of the Business Combination, the Combined Company’s name will be changed to ANEW MEDICAL, INC. On November 1, 2021, the company acquired ANEW Oncology, Inc., a Delaware corporation as a wholly-owned subsidiary.
ANEW MEDICAL is dedicated to realizing the potential of biologic, cell and gene therapies to offer transformative patient outcomes in areas of high unmet medical need by extending the reach of protein, cell, and gene therapies to highly prevalent neurodegenerative disorders like amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease as they are universally fatal neurodegenerative diseases. The company has assembled a portfolio of gene therapy candidates in partnership with leading scientific institutions and have built a team with extensive experience in the biotechnology commercialization and gene therapy space. The lead product candidates are the gene therapy candidate for ALS therapy termed AMI-202 (“AAV.myo-s-KL”), and the gene therapy candidate for Alzheimer’s diseases termed AMI-101 (“AAV9-s-KL”). All of these candidates are in pre-clinical development.
The company plans on building integrated internal development capabilities from product development through commercialization and focus on accelerating the pace of product development in the clinic.
The mailing address of ANEW MEDICAL’s principal executive office is 13576 Walnut Street Omaha, NE 68144. Its telephone number is (402) 239 5556.
ANEW MEDICAL’s common stock is currently traded on the Pink market tier of the OTC Markets Group under the trading symbol “LEAS.” The closing price of ANEW MEDICAL’s common stock on February 9, 2024 was $0.0016.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001907223/000121390024013467/fs42024a8_redwoods.htm
Do you think that the Leas CEO was waiting for the expert market to get rid of old shareholders ?
Everyone holding this has been rugged and you still won’t accept it! Keep dreaming…keep dreaming! And when you see all those zeros after the decimal point and not before it, wake up and smell the coffee!
? Price is showing something off
Really?… after all this.. read something .. smh
Do u think theres no merger?
I thought this would be untradeable...
Just about every one of the IPO public investors redeemed their shares, leaving the founders and a few other service providers and insiders only. The redemption took just about all of the cash out of the treasury, so ANEW is starting out cashless.
On the LEAS side, the CEO controls the vote, and it is likely he’s going to mathematically do the RS he’s said all along he wants to do and award 99% of those RWOD shares to the preferred shareholders. He’s already taking 1.4M of those shares for himself.
They bought 1000 shares for $0.20 cents a share! Crazy
On the expert market, the stock can trade, but quotes of the bid and ask cannot be made public, shareholders/investors are flying blind. That’s why volume essentially goes to zero.
$LEAS When stocks go to the Expert market they are not available for trade on the Open Market...but can be bought and sold by marketers and brokers and they usually shred the price.
I do not believe this will have any affect on the Merger or the share conversion.
$LEAS $RWOD $WENA
LEAS remains on Scam Alert!
Everything looks to be on course.
No new PRs or Filings...but no red flags either.
$LEAS $RWOD $WENA
when will it release is the magic question
$LEAS $RWOD its happening
"When a SPAC merges, SPAC shareholders must believe they will receive about $10 per share in value to justify giving up their option to redeem at about $10. Target shareholders, however, will not agree to a merger unless they receive shares in the post-merger company at least equal to their estimation of the pre-merger value of their shares. Therefore, if target shareholders value SPAC shares only at their cash value, and negotiate a deal based on that value, SPAC shareholders will see their shares fall in price following the merger. For example, for the median SPAC with $6.67 in cash per share before the merger, shares would drop to $6.67 after the merger. This would mean the target has gotten an even deal and the SPAC shareholders have borne the cost of the SPAC’s dilution. If both target and SPAC shareholders are to break even or come out ahead, the merger must create sufficient surplus to fill the hole created by the SPAC’s dilution."...
I know but I see it on think or swim :o)
It’s expert market. There is no level 2, no quotations, bid, ask, not allowed.
so is this going to trade under Rwod symbol first or wena ?...
Sounds like we got rug pulled…. No filing either
really ,so you like wena :o)
+>>>LEAS - Yippie Yo Ki Yay!
CC
That is good.Keep my fingers crossed for all.
Another trader comment: Retransmit
i called my fidelity.....they aint no shit ....lolol told me check news and broadcasting.....I still BULLISH AS ALL HELL
Love to see some movement on this.
I thought we were going to be WENA but either way I'm excited to see this play out.
Followers
|
900
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
155603
|
Created
|
10/19/07
|
Type
|
Free
|
Moderators |
Medical product development and commercialization. The Company recently acquired five generic oncology drugs approved and manufactured in Germany and they plan to gain approval for these drugs in the US in 2023. The Company is preparing for a pivotal Phase 3 study of an anti-cancer antibody product that is highly similar to Genentech/Roche's brand name Avastin (bevacizumab), the Company has licensed a needle-free jet injector for drug delivery, and the Company is in the pre-clinical stages of development of a gene therapy product candidate based on the delivery of a human alpha-Klotho gene and protein to prevent and/or treat neurodegenerative diseases such as Alzheimer's and Lou Gehrig's disease (ALS). Other product candidates will stem from these platform technologies of pharmaceuticals, biologics, and gene therapy.
The Company's medical R&D facilities are in the U.S. (near the University of Nebraska Medical Center, Omaha, Nebraska) and in Barcelona, Spain (Autonomous Universitat de Barcelona). Each R&D facility is comprised of over 4,000 sq ft of R&D and office space, currently leased and equipped with research equipment, incubators, tissue culture facilities for production of plasmid DNA, HEPA-filtered hoods for aseptic handling, and testing equipment (PCR, spectrophotometers, microscopes, etc). The generic oncology drugs are manufactured in Germany. With future funding, the Company plans to acquire or build a GMP manufacturing facility to supply novel plasmid DNA ("transgenes") to be used in gene therapy programs, to provide contract manufacturing revenue, and for commercial product manufacturing.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |